Table 1 Patient demographics and baseline disease characteristics
Characteristic | Daratumumab 16 mg/kg (n = 32) |
|---|---|
Age | n = 32 |
 Median (range), years | 56.0 (22–78) |
 < 65 years, n (%) | 24 (75.0) |
 65–74 years, n (%) | 7 (21.9) |
 ≥ 75, n (%) | 1 (3.1) |
Sex, n (%) | n = 32 |
 Male | 23 (71.9) |
 Female | 9 (28.1) |
Asian, n (%) | 32 (100) |
ECOG PS score, n (%) | n = 32 |
 0 | 14 (43.8) |
 1 | 15 (46.9) |
 2 | 3 (9.4) |
Median (range) time since diagnosis, months | 24.0 (3.1–185.4) |
Percentage of CD38 expression | n = 22 |
 Median (range), % | 45.0 (0–100) |
 ≥ 0% to 49%, n (%) | 11 (50.0) |
 ≥ 50%, n (%) | 11 (50.0) |
H-score of CD38 expression | n = 22 |
 Median (range) | 67.5 (0–300) |
 ≥ 0 to 49, n (%) | 10 (45.5) |
 ≥ 50, n (%) | 12 (54.5) |
Plasma EBV-DNA, kIU/L | n = 31 |
 Median (range) | 3800.0 (0–11,291,151) |
β2 microglobulin, mg/L | n = 31 |
 Median (range) | 3.0 (1.7–11.5) |
Site of disease involvement at initial diagnosis, n (%) | n = 31 |
 Upper aerodigestive tract only | 17 (54.8) |
 Extra-upper aerodigestive tract only | 5 (16.1) |
 Both | 9 (29.0) |
PINK, n (%) | n = 31 |
 Low | 8 (25.8) |
 Intermediate | 15 (48.4) |
 High | 8 (25.8) |
PINK-E, n (%) | n = 30 |
 Low | 9 (30.0) |
 Intermediate | 13 (43.3) |
 High | 8 (26.7) |
Median (range) prior lines of therapy | 2 (1–8) |
Prior lines of therapy, n (%) | n = 32 |
 1 | 11 (34.4) |
 2 | 8 (25.0) |
 ≥ 3 | 13 (40.6) |
Prior therapies, n (%) | n = 32 |
 L-asparaginase–containing regimen | 27 (84.4) |
 Radiotherapy | 21 (65.6) |
 Cancer-related surgery/procedure | 15 (46.9) |
 Anthracycline-based regimen | 8 (25.0) |
 Autologous stem cell transplant | 4 (12.5) |